Martin F - Search Results

1

The making of the minibody: an engineered beta-protein for the display of conformationally constrained peptides.

Tramontano A, Bianchi E, Venturini S, Martin F, Pessi A, Sollazzo M. Tramontano A, et al. Among authors: martin f. J Mol Recognit. 1994 Mar;7(1):9-24. doi: 10.1002/jmr.300070103. J Mol Recognit. 1994. PMID: 7986569

2

The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6.

Martin F, Toniatti C, Salvati AL, Venturini S, Ciliberto G, Cortese R, Sollazzo M. Martin F, et al. EMBO J. 1994 Nov 15;13(22):5303-9. doi: 10.1002/j.1460-2075.1994.tb06864.x. EMBO J. 1994. PMID: 7957096 Free PMC article.

3

Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed beta-protein IL-6 antagonist.

Martin F, Toniatti C, Salvati AL, Ciliberto G, Cortese R, Sollazzo M. Martin F, et al. J Mol Biol. 1996 Jan 12;255(1):86-97. doi: 10.1006/jmbi.1996.0008. J Mol Biol. 1996. PMID: 8568877

4

A loop-mimetic inhibitor of the HCV-NS3 protease derived from a minibody.

Martin F, Steinkühler C, Brunetti M, Pessi A, Cortese R, De Francesco R, Sollazzo M. Martin F, et al. Protein Eng. 1999 Nov;12(11):1005-11. doi: 10.1093/protein/12.11.1005. Protein Eng. 1999. PMID: 10585507

5

Engineering minibody-like ligands by design and selection.

Sollazzo M, Venturini S, Lorenzetti S, Pinola M, Martin F. Sollazzo M, et al. Among authors: martin f. Chem Immunol. 1997;65:1-17. Chem Immunol. 1997. PMID: 9018870 Review. No abstract available.

6

Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.

Dimasi N, Martin F, Volpari C, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R, Steinkühler C, Sollazzo M. Dimasi N, et al. Among authors: martin f. J Virol. 1997 Oct;71(10):7461-9. doi: 10.1128/JVI.71.10.7461-7469.1997. J Virol. 1997. PMID: 9311825 Free PMC article.

7

Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.

Dimasi N, Pasquo A, Martin F, Di Marco S, Steinkühler C, Cortese R, Sollazzo M. Dimasi N, et al. Among authors: martin f. Protein Eng. 1998 Dec;11(12):1257-65. doi: 10.1093/protein/11.12.1257. Protein Eng. 1998. PMID: 9930676

8

Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease.

Martin F, Volpari C, Steinkuhler C, Dimasi N, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R, Sollazzo M. Martin F, et al. Protein Eng. 1997 May;10(5):607-14. doi: 10.1093/protein/10.5.607. Protein Eng. 1997. PMID: 9215580

9

Design of selective eglin inhibitors of HCV NS3 proteinase.

Martin F, Dimasi N, Volpari C, Perrera C, Di Marco S, Brunetti M, Steinkühler C, De Francesco R, Sollazzo M. Martin F, et al. Biochemistry. 1998 Aug 18;37(33):11459-68. doi: 10.1021/bi980283w. Biochemistry. 1998. PMID: 9708981

10

Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study.

Sabatini U, Boulanouar K, Fabre N, Martin F, Carel C, Colonnese C, Bozzao L, Berry I, Montastruc JL, Chollet F, Rascol O. Sabatini U, et al. Among authors: martin f. Brain. 2000 Feb;123 ( Pt 2):394-403. doi: 10.1093/brain/123.2.394. Brain. 2000. PMID: 10648446

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,552 results

Search Page

Filters